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Abstract
Background Machine learning (ML) allows the explo-
ration and progressive improvement of very complex
high-dimensional data patterns that can be utilised to
optimise specific classification and prediction tasks,
outperforming traditional statistical approaches. An
enormous acceleration of ready-to-use tools and ar-
tificial intelligence (AI) applications, shaped by the
emergence, refinement, and application of powerful
ML algorithms in several areas of knowledge, is on-
going. Although such progress has begun to perme-
ate the medical sciences and clinical medicine, imple-
mentation in cardiovascular medicine and research is
still in its infancy.
Objectives To lay out the theoretical framework, pur-
pose, and structure of a novel AI consortium.
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Methods We have established a new Dutch research
consortium, the CVON-AI, supported by the Nether-
lands Heart Foundation, to catalyse and facilitate the
development and utilisation of AI solutions for exist-
ing and emerging cardiovascular research initiatives
and to raise AI awareness in the cardiovascular re-
search community. CVON-AI will connect to previ-
ously established CVON consortia and apply a cloud-
based AI platform to supplement their planned tradi-
tional data-analysis approach.
Results A pilot experiment on the CVON-AI cloud was
conducted using cardiac magnetic resonance data. It
demonstrated the feasibility of the platform and doc-
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What’s new?
 Artificial intelligence (AI) is a promising method
for analysis and interpretation of complex data.
 In contrast to other fields, little AI can be
found in the cardiovascular research arena in
the Netherlands.
 The authors feel there is an urgent need to catal-
yse the update of AI in the cardiovascular re-
search arena in the Netherlands.
 The CVON-AI consortium aims to create an eas-
ily accessible cloud-based platform for intuitive
AI implementation in a wide spectrum of cardio-
vascular datasets.
 Our goal is to demonstrate the clinical applica-
bility and value of AI in cardiovascular disease,
and to extend the analytical methodology of on-
going Dutch cardiovascular research consortia.
umented excellent correlation between AI-generated
ventricular function estimates as compared to expert
manual annotations. The resulting AI solution was
then integrated in a web application.
Conclusion CVON-AI is a new consortium meant
to facilitate the implementation and raise awareness
of AI in cardiovascular research in the Netherlands.
CVON-AI will create an accessible cloud-based plat-
form for cardiovascular researchers, demonstrate the
clinical applicability of AI, optimise the analytical
methodology of other ongoing CVON consortia, and
promote AI awareness through education and train-
ing.
Keywords Machine learning · Artificial intelligence ·
Cardiovascular disease · CVON-AI consortium
Background
Cardiovascular disease and research in the
Netherlands
Cardiovascular disease still represents a major cause
of morbidity and mortality in Europe [1]. Although it
has become the second largest cause of mortality in
the Netherlands, it has been estimated that cardio-
vascular disease burden will increase by 50% within
the next 25 years [2]. The profile of cardiovascu-
lar disease includes acute (coronary syndromes) and
chronic conditions (heart failure, valvulopathies, and
atrial fibrillation) for which diagnostic and therapeu-
tic improvements have been achieved in the last few
decades. Nevertheless, the nature of cardiovascular
disease is that of a multifactorial system that encom-
passes a complex bus of genetic, biological, environ-
mental, and lifestyle determinants. This complexity is
also visible in the variability of the disease expression
itself, which constitutes an added challenge for our
efforts to mitigate its advance.
Great efforts have been directed towards the ex-
tensive characterisation of cardiovascular risk factors,
as they hold promise in the generation of mecha-
nistic models that allow for better prevention, detec-
tion, and treatment of cardiovascular disease in both
men and women. To address the increasing burden
of cardiovascular disease, the Dutch Heart Founda-
tion has prioritised three main areas of interest since
2014 [3], specifically: ‘early recognition of cardiovas-
cular disease’, ‘cardiovascular disease in women’, and
‘improved treatment of heart failure and arrhythmia’.
Consequently, a number of experimental and clini-
cal initiatives, in the form of research consortia, have
been established. Such consortia have collected large
amounts of patient data that harbour enormous po-
tential to enlarge our knowledge on the mechanis-
tic pathways in cardiovascular disease in order to im-
prove early recognition, facilitate proper clinical deci-
sion-making, and generate personalised therapeutics.
However, the planned and performed methodological
approaches within these consortia mainly rely on tra-
ditional statistical analyses, which may be insufficient
to discover more complex relations within the data
that may be relevant in the study of cardiovascular
disease.
Artificial intelligence and machine learning
Artificial intelligence (AI) is defined as ‘the theory and
development of computer systems that are able to
perform complex tasks requiring human level intelli-
gence’ [4]. Although several other definitions are used,
all propose the use of computer-based models that
can perform specific activities with a level of com-
plexity at least comparable to (and likely beyond) that
of human level intelligence. Machine learning (ML),
on the other hand, represents the family of algorithms
able to elucidate and implement (i.e. learn and apply)
complex patterns from available data through itera-
tive optimisation processes to perform prediction or
classification tasks in new data [5]. The niche of ML is
located at the intersection of computer science, statis-
tics, and subject-matter expertise [6]. A key feature
of machine learning is its capability to explore large
amounts of data for very high-dimensional non-lin-
ear interactions which would likely be unattainable
through traditional modelling [7]. The concepts of AI
and ML have inaccurately been used as synonyms.
However, it is relevant to know that AI rather relates
to the application of task optimisation systems while
ML describes the methods or algorithms that under-
pin such applications.
Historically, an initial idea of programming
human level intelligence into machines aroused in-
terest during the 1950s and 1960s. Later on, a second
AI development wave was initiated during the 1990s
with the incorporation of various ML algorithms that
could elucidate (i.e. learn) dependencies between
structured data and outcomes of interest. Despite the
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value of these models and the emerging knowledge
about data inference, ML only flourished to a limited
extent, mainly due to limited computational power,
limited size of available datasets, and the need for
expert-designed features. Nowadays, unrestrained
scalability of data storage and availability of novel
graphics processing units (GPUs) have turned ML
theories into useful AI applications. Moreover, these
factors have allowed the emergence of a novel itera-
tion of a particular set of ML algorithms called neural
networks. Such refinement (i.e. deep neural networks)
has delivered complex and powerful algorithms that
are remarkably effective in image processing and are
currently conceptualised as deep learning.
This phenomenon has permeated several domains
of scientific knowledge with immediate extension
to key performance areas in industry (e.g. Google’s
search engine, e-mail spam filters, game mastering by
Alpha Zero [8], and driverless cars by Tesla). Notably,
the open-source character of the field has caused
further acceleration with free software tools and li-
braries, as well as the publication of many of the
codebases [9–11]. At the same time, implementation
of AI in medical sciences has begun and is quickly
gaining pace [12, 13]. For instance, in April 2018 the
first AI-based automatic medical tool was cleared by
the FDA for the detection of diabetic retinopathy [14].
It is clear, therefore, that promoting AI applicability
in cardiovascular medicine is warranted.
The cloud
In computing, the cloud is defined as ‘a network of re-
mote servers hosted on the Internet and used to store,
manage, and process data instead of local servers or
personal computers’ [15]. After initially investing pri-
marily in storage services, major companies in the
field of computing have shifted their focus to provid-
ing customers with flexible, highly scalable platforms
to run their applications on. Integration of, and com-
munication between, these systems is supplied and
managed by cloud computing providers, without the
need for the user to be aware of the hardware con-
figuration. Cloud systems adapt instantaneously to
the customers’ changing demands, and most of them
work on a pay-per-use basis. The on-demand avail-
ability of these systems saves customers’ start-up in-
vestments and releases them from the need to have
expertise and hire personnel to maintain large-scale
computing systems. Consequently, the cloud pro-
vides researchers with a technical platform that allows
them to develop small-scale, low-budget pilot or try-
out studies that can be performed on a relatively small
number of computers, and that can later scale up into
promising full projects.
Applicability of AI in cardiovascular research
Three elements are necessary for the successful im-
plementation of machine learning-based AI, namely:
sufficiently large amounts of data, large computa-
tional power provided by GPUs, and a sufficiently
complex problem. The last-mentioned is necessary
because it is likely that simpler problems may be ad-
equately and robustly modelled through traditional
statistical approaches [16]. The current standard in
the Netherlands for these elements has been achieved
through large datasets emerging from ongoing Dutch
Cardiovascular Research (CVON) consortia, national
high-performance computing clusters, and cloud-
based computing services, as well as the recognition
of the complexity of both the pathophysiological and
clinical spectrum of cardiovascular disease.
Considering the current state of development in
ML algorithms, the availability of cloud infrastructures
and the advancement of AI into medical sciences, we
have initiated a novel CVON consortium, the CVON-
AI. Hence, the present report aims to outline its pur-
poses and envisioned structure, as well as to report on
the preliminary results that it is delivering.
Methods
The CVON-AI concept
The CVON-AI consortium has been designed to catal-
yse the implementation of AI into cardiovascular dis-
ease research through: the application of ML algo-
rithms including deep learning in large and diverse
datasets, their further optimisation, the facilitation
of accessibility to these methods to enhance large-
scale collaborative research, and the promotion of AI
awareness in the Netherlands. Figure 1 depicts the
general architecture of the CVON-AI consortium.
The CVON-AI consortium will initially demonstrate
the value of AI implementations in comparison with
the planned standard statistical methodologies in al-
ready existing cardiovascular research scenarios (Con-
solidation). It ultimately strives to integrate a secure
and accessible platform that allows for the utilisa-
tion of AI methodology in CVON initiatives and other
available and future data-generating initiatives (Ap-
plication). Thereon, the adequacy and magnitude of
contribution of AI integration into clinical decision-
making will be evaluated as a direct application use
case through the integration of CVON-AI-generated
ML models into clinical decision support tools that
will be validated in randomised studies. These pro-
ceedings will be undertaken along with parallel and
sustained efforts to introduce, promote, train, and
constantly update (potential) users, collaborators, and
other interested parties in general (Expansion). The
CVON-AI consortium will be open to other investi-
gators joining and using the developed platform and
techniques at minimal costs.
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Fig. 1 Cloud platform ar-
chitecture
A cloud-based platform
A cloud-based platform will be developed to allow the
generation of a web interface (with an open, standard-
ised application programming interface (commonly
known as API)) consisting of several building blocks
to execute stepwise processes such as: secure import-
ing of (different types of) study data, optional sharing
of study data, standard and customisable preprocess-
ing actions on study data, utilisation of standard pre-
installed and customisable ML (in general, and deep
learning in particular) frameworks, accessing consor-
tium/project-specific workspaces, training of AI solu-
tions, and their deployment with real-time interaction
via the web.
The platform will deliver a standard set of un-
trained and pretrained models that will be made
available to participating consortia over the course of
time. The consortia will keep track of, and publish
an index of, different versions of existing models that
will be made available through the platform, and that
will also remain available to the consortia’s projects
after improved versions have been released. Addi-
tionally, each consortium will have its own projects
and models, trained for a specific purpose, based
on a corresponding dataset. Different approaches
towards model architecture and parameter tuning,
as well as the resulting output, may be retained in
a project’s workspace, and physically persisted to
cloud storage, to be selected and reviewed afterwards,
at any given time.
Data quality and safety
The CVON-AI platform will promote the reuse and
combination of datasets that are uploaded to the
platform. Data will be verified for aspects such as
completeness, anonymisation, consistency of struc-
ture, and reliability. Especially for the purpose of
combining datasets, compatibility and mapping of
data structures will be central features that will be
deeply embedded in the data collection components
of the platform.
CVON-AI will make use of cloud technology made
available by leading technology companies for the
creation of an accessible platform. Consequently,
platform security will rely on technology that utilises
proven measures of authentication, authorisations,
backup/recovery, and secure data storage. Although
the data that will be processed on the CVON-AI plat-
form will be de-identified, CVON-AI will verify the
cloud technology’s compliance with data protection
regulations and guidelines.
Pilot experiment on the CVON-AI cloud platform
As an exploratory step to evaluate and to showcase
the feasibility and workflow of the CVON-AI towards
the development of a platform for cardiovascular re-
search, a pilot project was undertaken to navigate
through the Google Cloud Platform’s technical hori-
zon with a practical problem in hand. The objective
was to train and test a deep learning model (Fig. 2a) in
the cloud to perform an automated tracing of the left
ventricular cavity (LVC), the myocardium, and right
ventricular cavity (RVC) on short axis views from cine
cardiac magnetic resonance (CMR) images in order
to obtain application-based interactive estimates of
cavity volumes and ejection fraction as widely used
cardiac function measures.
Raising AI awareness
Dissemination constitutes an essential objective of
the CVON-AI consortium. Promotion is expected to
take place via website access, presentations, road-
show events, as well as education and training work-
shops. Involvement of cardiovascular scientists will be
boosted through the involvement of companies that
directly benefit from the project and of program lead-
ers and Young-Talent-Program principal investigators
from existing CVON consortia.
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Box 1 The CVON-AI pilot: technical implementa-
tion
 The trained model was an implemented vari-
ation of the U-Net first published by Ron-
neberger et al. [18], which has been shown
to be a well-performing model for biomedical
image segmentation.
 The code base was locally developed in Python
with Keras (Tensorflow backend) and versioned
with a GitHub hosted git repository.
 From the source images, a random selection of
80% of the patients was taken to train the model;
the other 20% was used to test the model.
 Sixteen central processing units and a single
Nvidia Tesla P100 graphics processing unit were
recruited and training duration was minimised
to a scale of minutes (in contrast to hours).
 The program then automatically specified the
appropriate images to be used for analysis (us-
ing several machine learning models). On the
selected images annotations are calculated us-
ing the trained U-Net.
 Areas are calculated from the segmented sur-
faces for all short axis discs of all frames that have
been recorded in the patient’s study, taking into
account the image resolution (cm/pixel), which
can be extracted from the DICOM images’ meta-
data. Volumes of the different structures were
calculated per frame by adding frustum volumes









 with Ai being the ordered areas of the segmented
slices and n=number of slices –1.
 The frame with the largest volume is chosen to
be end diastole, and from this frame the end-
diastolic volume is selected. Likewise, the frame
with the smallest volume is used for the selection
of the end-systolic volume.
 The hard dice index was utilised as the main
evaluation metric (Eq. 2) and was calculated for
each structure and for train and test set sepa-
rately.







with TP (true positive) being the surface made
up by predicted white pixels that match white
pixels in the ground truth image, FP (false posi-
tive) being the surface of predicted white pixels
that do not have matching white pixels in the
ground truth, and FN (false negative) the sur-
face of predicted black pixels that do not have
matching black pixels in the ground truth.
Preliminary results
Pilot experiment and platform implementation
Images from 222 patients involved in the GIPS-III
study [17] were used in this pilot project. Manual
annotations of end-diastolic and end-systolic frames
were performed by imaging core laboratory techni-
cians as reference for evaluation of the model. The
data were uploaded to the Google Cloud Platform
Storage and the code base was imported from a cen-
tral source-code management system. Subsequently,
a deep learning model was trained and tested (see
Box 1). Notably, the utilisation of the Google Cloud
Platform enabled faster training, testing and pre-
diction, as more computational resources can be
reserved for particular use from the Google servers on
demand. The results demonstrated excellent correla-
tion between AI-generated ventricular function esti-
mates and the expert manual annotations as shown
on the right side of Fig. 2.
The finalised model was then integrated into a web
application (see Fig. 3) with the help of the Google
Cloud Platform App Engine. The application was ulti-
mately able to receive a CMR of a single new patient
(i.e. not yet seen by the system) and to directly gen-
erate the proper segmentations of the LVC, RVC, and
myocardium along with an output of estimated vol-
umes and ejection fractions. Additionally, radial strain
was calculated for the myocardium and visualised in
colour for demonstration of asymmetry in the heart
dynamics.
This successful implementation in the pilot study
demonstrated the feasibility of the workflow intended
by the CVON-AI consortium. This approach exem-
plified how CVON-AI will undertake training, valida-
tion, and fine-tuning of tailored ML models to anal-
yse incoming showcase data from collaborating CVON
consortia (CVON EARLY-SYNERGY and CVON RACE-
V, but open for additional collaborations). This will
allow timely comparison of the achieved AI results to
those obtained through the analysis stated in their
original research plan. It is expected that analyses
undertaken through the CVON-AI initiative will ren-
der an advantage beyond traditional approaches, and
therefore better exploit the potential of the large-scale
data provided by these consortia.
AI awareness
As an initial step in the raising of AI awareness
through the CVON-AI consortium, GoDataDriven
(a constitutional partner of CVON-AI) supported the
organisation of a ‘challenge’ in the Dutch Data Sci-
ence Week (visit: https://www.youtube.com/watch?
v=5rW7EchLK0Y), which achieved substantial involve-
ment in an innovative environment.
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Fig. 3 Model-backed demo web application with segmen-
tations on a limited set of magnetic resonance images from
the GIPS-III study. LVC volume of the left ventricular cavity,
RVC volume of the right ventricular cavity, LVM mass of the
left ventricular tissue, calculated from the left ventricular con-
tours at each consecutive frame
Upcoming challenges
Although AI has received positive responses from
professionals and consumers in other areas of ev-
eryday life, acceptance of AI solutions in healthcare
will surely need a wider timeframe for robust imple-
mentation considering healthcare providers, patients,
and governing bodies that oversee regulations. Au-
tomating diagnostics and decision-taking on patient
treatments is a delicate matter that should be ad-
dressed comprehensively. Approval and validation of
developed models will be of even greater importance,
compared to the governance of release trajectories of
classical software solutions. Additionally, quality as-
surance of developed models can be precarious, since
both training and validation rely on ground truth data
that has been created by human observers, and must
be considered potentially biased. However, if these
aspects are taken care of accurately, and in detail,
the provided techniques can eventually show their
true potential, by improving patient care, modifying
disease outcomes, and providing higher productivity
at a lower cost.
Conclusion
CVON-AI is a new consortium meant to facilitate the
implementation and raise awareness of AI in cardio-
vascular research in the Netherlands. It is emerging at
a time of rapid developments in ML algorithms that
have boosted the suitability of AI solutions in many
areas of knowledge. CVON-AI will create an accessible
cloud-based platform for cardiovascular researchers,
demonstrate the clinical applicability of AI, optimise
the analytical methodology of other ongoing CVON
consortia, and promote AI awareness through educa-
tion and training.
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